Lenire Tinnitus Treatment Device

03/07/2026

Happy Fourth of July from everyone at Neuromod!

We wish our colleagues, partners, and everyone celebrating a wonderful Independence Day as the United States marks its 250th anniversary.

If you're enjoying fireworks with friends and family, remember to protect your hearing by wearing hearing protection. A simple step can help protect your hearing while you celebrate. 🎆👂

Wishing you a safe, happy, and memorable Fourth of July!

15/05/2026

CTV News interviewed Toronto-based business professional, Jim Gray, about his life with chronic tinnitus and his life-changing relief after .

"I tried to manage it through exercise, through diet, through acupuncture, even tried some cognitive therapy, which was helpful, but didn't attack the underlying problem," said Jim Gray. "Lenire has completely changed my life, within days of trying Lenire, my tinnitus had been reduced by 90%."

Jim is just one of 43% of Canadians (11.2m) report experiencing tinnitus in their lifetime with 37% of Canadians (9.2m) report experiencing tinnitus in the past year according to data from a Canadian Health Measures Survey (CHMS).

CTV News' Pauline Chan also spoke with Neuromod CEO, Dr. Ross O'Neill about Lenire, and Sunnybrook's Maria Simone about the causes of tinnitus.

Lenire tinnitus treatment device now available in Canada through 21 clinics across Alberta, British Colombia, Manitoba, Ontario, and Québec.

Further expansion is expected in 2026 to meet the underserved clinical needs of Canada's large tinnitus patient population. You can find a clinic near you by visiting https://www.lenire.com/find-a-clinic/

01/05/2026

We’re excited to share that Peachtree Hearing will be hosting Dr. Ross O'Neill, CEO of Neuromod and inventor of hashtag , on May 14th at 7:00 PM in Atlanta, GA.

Join Melissa Wikoff, Au.D. and her team, for an exclusive evening to learn more about hashtag , the only FDA-approved tinnitus treatment and hear directly from Dr. O’Neill about the science and success behind it.

Spaces are limited, so be sure to secure your spot!

10/04/2026

The Atlanta VA Health Care System marked a significant milestone in Veteran care on April 2, 2026, with the first use of the Lenire tinnitus treatment technology.

Profit Lucy, an Army Veteran, is also among the first patients at the facility to receive the treatment. “This is an exciting advancement for Veterans who struggle daily with tinnitus,” said Lucy. “Tinnitus can cause sleep, social mobility and focus issues. Being able to receive this ground-breaking tinnitus treatment device gives me great confidence in the impact it can have on improving my quality of life.”

3.2 million U.S. Veterans are living with tinnitus making it the #1 service-connected disability according the the latest Annual Benefits Report.

Neuromod is proud to support U.S. Veterans and help those who served get relief from chronic noise. You watch the video below or read the full story on the Veterans Affairs website.

07/04/2026

Lenire by Neuromod is now available in Canada through 21 clinics across Alberta, British Colombia, Manitoba, Ontario, and Québec.

43% of Canadians (11.2m) report experiencing tinnitus in their lifetime with 37% of Canadians (9.2m) report experiencing tinnitus in the past year according to data from a Canadian Health Measures Survey (CHMS).

Lenire's clinically-proven bimodal neuromodulation offers chronic tinnitus sufferers hope that they can get relief from the comfort of home.

“Lenire has been a miracle that has changed my life” – Toronto-based Lenire patient, Jim Gray.

You can find more information about Lenire's Canadian launch, as well as a full list of clinic locations on the Lenire Blog.

Lenire tinnitus treatment device now available in Canada through clinics in Alberta, British Colombia, Manitoba, Ontario, and Québec.

24/03/2026

Lenire by Neuromod is now available in The Netherlands. The ground-breaking device is available through HearConsult locations in Utrecht and Mijdrecht, expanding access to the treatment in a country where over 2 million adults are affected by tinnitus.

According to a recently published paper, the incidence of tinnitus in The Netherlands increased by 33% between 2012 and 2021, with the largest increase seen in adults aged 20 to 44.

“As a researcher, I spend quite a lot of time focusing in quiet spaces, and the noise from my tinnitus was very distracting, and it also made socialising difficult,” says Jan van Dam, an Utrecht-based researcher who used the device. “I found Lenire’s clinical research compelling and now, after treating my tinnitus with the device, the tinnitus is much quieter, and it no longer annoys me.”

You can learn more about Lenire's availability in The Netherlands on The Hearing Review.

Neuromod Devices has partnered with HearConsult to introduce the bimodal neuromodulation system in The Netherlands.

09/03/2026

Neuromod is at the DoubleTree by Hilton in Orlando, FL for the 2026 Joint Defense Veterans Audiology Conference.

Visit Booth 11 at to speak with the team about , the first and only FDA-approved bimodal neuromodulation device for tinnitus.

Lenire is now a treatment option for the 3.2 million veterans living with tinnitus through the U.S. Department of Veterans Affairs.

Visit https://www.lenire.com/lenire-for-veterans/ to learn how Lenire can give Veterans relief from tinnitus.

19/02/2026

Read Mass Device's coverage of the second real patient analysis of U.S. tinnitus patients treated with . The paper, written by Dr. Craig Kasper of NYHD | Institute For Hearing & Balance, found that 81.8% of 140 patients treated with Lenire reported relief from tinnitus and had a mean reduction of 23.8 points on the THI scale.

Results reported in this paper, published in ASHA Journals, are consistent with the first analysis of real world U.S. tinnitus patient's treated with Lenire, which was published in Nature Portfolio.

Neuromod Devices today announced new data supporting the use of its Lenire tinnitus treatment device in U.S. patients.

06/02/2026

In this conversation with Patrick A. Lynch, Esq., MBA, CEO of the American Tinnitus Association, Dr. Ross O'Neill, Founder & CEO of Neuromod and Dr. Hubert Lim, Chief Scientific Officer of Neuromod Devices , answer the questions that matter most, drawing on clinical trial data and real-world evidence from Lenire providers.

Whether you’re living with tinnitus, considering as a treatment option, or a provider exploring whether to offer Lenire, this conversation offers clear, practical guidance grounded in evidence and experience.

Is Lenire right for you? Drs. Ross O'Neill (Founder & CEO, Neuromod Devices) and Hubert Lim (Chief Scientific Officer) answer the questions that matter most,...

04/02/2026

84.1% of 97 Americans with bothersome tinnitus reported significant relief after treatment with bimodal neuromodulation device, Lenire, a new study has found.

Findings in this paper demonstrate the effectiveness of Lenire and indicate a strong correlation between THI and TFI treatment outcome measures.

The study, written by Dr. Brian Fligor Ph. D. and Dr. Miles Sabine Au. D. of Tobias & Battite Hearing Wellness in Boston, M.A., is now available on bioRxiv & medRxiv.

This paper is the third in a series of ongoing, real-world evidence publications that have been compiled from thousands of American tinnitus patients that have been successfully treated with Lenire by independent clinicians.

These results are consistent with Lenire's first two real-world analyses of U.S. tinnitus patients treated with Lenire. These papers were published in Nature Portfolio and ASHA Journals (The American Journal of Audiology).

You can read a breakdown of the paper on Audiology Online.

Real-world analysis of 97 Americans with bothersome tinnitus who were treated with Lenire has been made available on medRxiv, a preprint server for health sciences.